---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-020512"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2021-08-18T23:59:59+00:00"
generated_at: "2026-06-29T09:21:36.099019+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Provectus Biopharma approves up to $5M convertible loan; CFO invests $200K

## Summary
- Board approved financing term sheet for up to $5,000,000 unsecured convertible loan.
- Loan bears 8% interest, due in 12 months; convertible into Series D-1 Preferred at $2.862/share (each converts to 10 common shares).
- On Aug 16, 2021, CFO Heather Raines invested $200,000 via a 2021 Note under the same terms.
- Proceeds to fund drug discovery/development and general administrative expenses.
- Issuance exempt from registration under Section 4(a)(2) or Rule 506 of the Securities Act.

## SEC filing metadata
- accession: 0001493152-21-020512
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2021-08-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/0001493152-21-020512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315221020512/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-020512
- JSON: https://secwatch.observer/filing/0001493152-21-020512.json
- Plain text: https://secwatch.observer/filing/0001493152-21-020512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.